Bortezomib (PS-341)

Catalog No.S1013 Synonyms: LDP-341, MLM341

Bortezomib (PS-341) Chemical Structure

Molecular Weight(MW): 384.24

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.

Size Price Stock Quantity  
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 145 Publications

22 Customer Reviews

  • Indisulam dependent degradation of RBM39 can be blocked by bortezomib, a proteasome inhibitor. Cells were pretreated with indicated concentrations of bortezomib for 2 hours, followed by 6 hours of treatment with 2 μM indisulam. The effect of bortezomib is attenuated in a bortezomib resistant cell line.

    Science, 2017, eaal3755. Bortezomib (PS-341) purchased from Selleck.

    Effect of different proteasome inhibitors on dysferlin expression and on membrane resealing in cultured primary myoblasts. Primary myoblasts from patient 2 harboring a homozygous Arg555Trp DYSF mutation that were treated with the indicated amounts of bortezomib for 24 hours. Western blots of protein extracts were stained with anti-dysferlin antibodies and with anti–a-tubulin antibody as loading control.

    Sci Transl Med 2015 6(250), 250ra112. Bortezomib (PS-341) purchased from Selleck.

  • Pharmacologic inhibition of the proteasome blocks proplatelet formation in murine and human megakaryocytes. Human megakaryocytes were pretreated with vehicle or bortezomib, and megakaryocytes producing proplatelets (PP) were examined. Shown are representative transmission images and representative confocal images with wheat germ agglutinin (WGA; red) and phalloidin (green) staining. Scale bars: 50 um.

    J Clin Invest 2014 124(9), 3757-66. Bortezomib (PS-341) purchased from Selleck.

    Immunofluorescence showing HDAC4 localization in mouse primary osteoblasts treated with vehicle or PTH alone or in the presence of bortezomib. Primary osteoblasts treated with vehicle, PTH, or PTH plus bortezomib for 2 h using anti-HDAC4 and anti-b-actin antibodies.

    J Cell Biol 2014 205(6), 771-80. Bortezomib (PS-341) purchased from Selleck.

  • Effects of NF-kB inhibition on cell proliferation and apoptosis in Foxp3cKO prostate. A. Top left panels: Representative H&E staining of PIN lesions in ventral prostates of 60-week-old PBS- or bortezomib-treated Foxp3cKO littermates. Scale bar, 50 祄. Right graph: Quantification of Ki67-positive cells identified by IHC analysis (bottom left panels) as a measure of cell proliferation, performed with Scion Image software. Horizontal lines represent the average values. The p value was determined by two-tailed t test. B. Representative western blots showing p65 and nuclear p65 (N-p65) expression in prostates at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. C. Quantification of Bcl2l1 and Traf1/2 mRNA expression as a percentage of Hprt expression measured in microdissected mouse prostate epithelial cells by qPCR at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. Horizontal lines represent the average values. The p values were determined by two-tailed t test. D. Left panels: Representative images of TUNEL assays performed on prostates from PBS- or bortezomib-treated mice at 60 weeks of age. Insets show the apoptotic cells (green) in prostate glands. Scale bar, 100 祄. Right graph: Quantification of apoptotic cells in the ventral and dorsolateral prostates of PBS- or bortezomib-treated mice at 45 and 60 weeks of age. Horizontal lines represent the average values. The p value was determined by two-tailed t test. cKO, PB4-Cre4+Foxp3flox/y; wks, weeks; B/P, ratio of the mean value from bortezomib-treated mice to the mean value in PBS-treated mice. All experiments were repeated two times. Wks, weeks.

    Cancer Res 2015 75(8), 1714-24. Bortezomib (PS-341) purchased from Selleck.

    Inhibition of proteasome and lysosome or silencing of VCP and co-factors lead to the accumulation of OP-puro-labeled DRIPs adjacent to or within SGs. HeLa cells were co-treated for 45 min with OP-puro and arsenite (Ars.); where indicated, cells were pretreated with bortezomib (Bort.) overnight and/or ammonium chloride (NH4Cl) for 2 h 15 min. Cells were fixed and labeled with Alexa594-Azide and anti-TIA-1.

    Cell Death Differ 2014 21(12), 1838-51. Bortezomib (PS-341) purchased from Selleck.

  • Control wild-type and Fmn2–/–oocytes observed at different stages of meiotic maturation [prophase I (Pro I), NEBD, 3 hours and 8 hours after NEBD] using anti-Fmn2. wt + Bortezo, wild-type oocytes treated with 0.1μM Bortezomib for 90 minutes before fixation. All oocytes were observed using the same settings and the images treated the same way (three independent experiments). Red arrows indicate cortical labeling. Scale bar: 10μm.

    Development 2011 138, 2903-2908. Bortezomib (PS-341) purchased from Selleck.

    Immunofluorescence analysis for Ser536 p-NF-κB cellular localization of RS4;11cells treated with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. Cells were treated, collected at 22 h and reacted with an antibody to Ser536 p-NF-κB which was revealed by a Cy3-conjugated secondary antibody. DAPI was used to label nuclei.

    Oncotarget, 2015, 51: S659-S660. Bortezomib (PS-341) purchased from Selleck.

  • (B–C) LNCaP (B) and LNCaP-AI (C) cells were transiently transfected with sPLA2-IIa(-800)-Luc (0.5 μg). The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) without or with EGF (100 ng/ml) for 24 h. Luciferase assay was performed according to a standard protocol with Renilla luciferase as an internal control. Data are presented as the mean (±SD) of duplicate values of a representative experiment that was independently repeated for five times.

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

    LNCaP-AI cells were starved in 1% stripped medium for 24 h. The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) for 24 h. Cell culture medium was collected from each sample and subjected to ELISA for sPLA2-IIa. The condition medium samples were diluted 10 times for ELISA. Average of duplicate samples was converted to nanogram per milliliter against standard curve. The data represent one of five repeated experiments.

     

     

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

  • Cell viability of HCT116 cells treated with a single drug or with the addition of leucovorin.

    Sci Rep, 2017, 7(1):682. Bortezomib (PS-341) purchased from Selleck.

    The stable cell line HepAD38 was incubated for 18 h in the presence of the indicated amount of Bortezomib. The medium was removed and replaced by medium containing Bortezomib dissolved in PBS. In case of the control cells the same amount of PBS was added to the medium. 4 h later this procedure was repeated and again 14 h later the supernatant was collected. The amount of viral particles was quantified by real time PCR. HBV-genome quantification was done using COBAS® AmpliPrep/COBAS® TaqMan® HBV test (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s instructions. The assay shows relative values (the value for untreated control cells was arbitrarily set as 1) that are based on three independent experiments. The cell viability was analyzed by MTT assays. For does up to 50 nM no significant effect on cell viability was observed within 18h, for 100 nM the proportion of metabolically active cells was reduced to 83%.

    J Biol Chem 2010 285, 41074-41086. Bortezomib (PS-341) purchased from Selleck.

  • Western blot of extracts of infected cells treated with different proteasome inhibitors at different concentrations, reacted with the indicated antibodies. p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Time window treatment with proteasome inhibitors. (A) Scheme of the experiment performed with MA104 cells exposed to virus (OSU; MOI, 3) for 1 h and analyzed at the starting point and endpoint of the indicated time window treatments with DMSO, MG132, or bortezomib. (B) Western blot of cellular lysates derived from cells infected for the indicated time periods and treated with the proteasome inhibitors or DMSO. NI, noninfected cells. Blots were reacted with the indicated antibodies; p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Fluorescence analysis of viroplasm formation on NSP5-EGFP cells infected with rotavirus (OSU; MOI, 3) and treated or not treated with MG132 (10 M) or bortezomib (10 M) at different times p.i., as indicated. Cells were analyzed at the starting points (1 h, 3 h, 5 h, 7 h) and endpoints (9 h) of the inhibitor’s window treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Quantification of the accumulation of viroplasms in infected NSP5 -EGFP/MA104 cells. At different times p.i., cells were treated for 4 h with DMSO or the indicated proteasome inhibitor and the number of viroplasms/cell was quantified at the starting (1 h, 3 h, 5 h; white bars) and endpoints (5 h, 7 h, 9 h) of treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • PS-341 impairs FPV replication in A549 cells. (A and B)A549 cells were either pretreated for 1 h with different concentrations of PS-341 or with solvent only or were left untreated. Then, cells were infected with FPV at an MOI of 0.001 (A) or 0.05 (B). After virus inoculation cells were posttreated with different concentrations of PS-341. (A) At 24 h p.i. supernatants were obtained and progeny virus titers were measured by standard plaque assay. (B)Proteasome activity and the ability of PS-341 to inhibit the proteasome was determined 24 h p.i. (C) A549 cells were pretreated with 50 nM PS-341 or solvent or left untreated for 1 h. Afterwards cells were infected with FPV at an MOI of 0.0005. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or solvent or left untreated. After the indicated times p.i.supernatants were obtained and progeny virus titers were determined by standard plaque assay. Arrow bars in all experiments represent standard deviations of three independent experiments.

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    Early steps of viral replication within the first replication cycle are affected. (A) For time-of-addition kinetics analysis, A549 cells were either left untreated or were pretreated for 10 h or 1 h with 50 nM PS-341 before infection and additionally posttreated after infection. Cells were infected with FPV at an MOI of 0.005. After virus inoculation cells were posttreated with 50 nM PS-341. Then the proteasome inhibitor was added after virus inoculation (10 h, 1 h, and 30 min) or it was added at the different times p.i. as indicated (1 h, 2 h, 4 h, 6 h, and 8 h; cells were not pretreated before infection). At 9 h p.i. supernatants were obtained and progeny virus titers were determined by standard plaque assay. Shown is one representative experiment out of three independent experiments. (B) A549 cells were pretreated with 50 nM PS-341 or left untreated for 1 h. Afterwards cells were infected with avian FPV or human PR8 at an MOI of 1. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or left untreated. After the indicated times p.i. cells were lysed and analyzed by Western blotting for accumulation of viral proteins polymerase PB1 and matrix protein M1. Cellular protein ERK2 served as a control to demonstrate equal amounts of protein loading. Shown is one representative blot out of three independent experiments.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • A549 cells were treated with PS-341 at 50 nM for the indicated times or left untreated. Western blotting was performed with total cell lysates, using phospho-specific antibodies against JNK and the transcription factors c-Jun and ATF-2 or loading controls, respectively.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    Proteasome inhibition effect on biotinylation of MHC-Iα. (a) WB-ra of cellular extracts of HEK293 cells co-transfected with BAP-MHC-Ia and cyt-BirA (control) and, where indicated, with US2 or US11 in the absence (2) or presence of MG132 (MG; 50 μM for 4 h) or Bortezomib(Bort.; 50 μM for 4 h).

    PLoS One 2011 6, e23712. Bortezomib (PS-341) purchased from Selleck.

  •  

    KKU-M213 was treated with BTZ as indicated. Total cell lysate ( a) and nuclear extract (b) were prepared. Actin and γ -tubulin were loading controls for total and nuclear proteins, respectively.

    2011 Mireia Vila Gasull University of Porto. Bortezomib (PS-341) purchased from Selleck.

    Mireia Vila Gasull University of Porto. 2011;Mireia Vila Gasull . Bortezomib (PS-341) purchased from Selleck.

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Description Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.
Targets
20S proteasome [1]
(Cell-free assay)
0.6 nM(Ki)
In vitro

Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. [2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 MXXDfZRwfG:6aXOgRZN{[Xl? NV:z[3FuPTBizszN M3fsTFQ5KGh? M{faXWROW09? NFHabW1McWyuczDj[YxteyCkeTDtc5JmKHSqYX6gPVkm NUjzfHhbOTB2OUm2OFM>
OVCA 429 M{TJUWZ2dmO2aX;uJGF{e2G7 MYOzNFAhdk1? NGr5XGY1QCCq NHvI[JVFVVOR NV7uW21nTGm|coXweJMhcW62YXP0JI12dHSrY3XscJVt[XJidIXtc5Ihe3CqZYLvbYR{ MXyxNFk6QTd4Nh?=
RPMI8226 Ml3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPTc4NROTByIH7N NILkb4g1QCCq NI\3R2FFVVOR NWWxUph1UUN3ME2zNEBvVQ>? NHfrZ4kyOTNyNkS4PS=>
Dox40 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LlSlExOCCwTR?= MorsOFghcA>? NFz0O2NFVVOR NHzGdI5KSzVyPUSwJI5O NFrKOZoyOTNyNkS4PS=>
MR20 M{fGOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vlO|ExOCCwTR?= MmXsOFghcA>? MkDNSG1UVw>? M3jtcGlEPTB;MkCgcm0> NYn6S2xVOTF|ME[0PFk>
LR5 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HYcFExOCCwTR?= M{\CS|Q5KGh? MVjEUXNQ M1LENWlEPTB;MkCgcm0> M4TxfFEyOzB4NEi5
U266 NXrjU2hYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVyxNFAhdk1? NUXVW|g6PDhiaB?= NYjhclBHTE2VTx?= M372bWlEPTB;MzDuUS=> NY\aOpoxOTF|ME[0PFk>
IM-9 NVPDN3h{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYSxNFAhdk1? MXe0PEBp NIjjNWZFVVOR NF:3bW5KSzVyPU[gcm0> MUexNVMxPjR6OR?=
Hs Sultan MlLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPye40yODBibl2= M2fFe|Q5KGh? MnraSG1UVw>? NGfiWZVKSzVyPUKwJI5O MVixNVMxPjR6OR?=
PAM-LY2 NGXt[llHfW6ldHnvckBCe3OjeR?= NETzdY8yODBibl2= Mm[yNVIhcA>? MXnEUXNQ M2L3XWlvcGmkaYTzJG5HNc78QjDhZ5RqfmG2aX;u M1LaPVEyOzVyOUGz
PAM 212 MnjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLSWXMyODBibl2= NVOySmQ3PzJiaB?= MmXuSG1UVw>? NFnMbnNKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= NGXHRocyOTN3MEmxNy=>
PAM-LY2 MkXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHUbnhrOTByIH7N Mln5O|IhcA>? MVjEUXNQ NYfQSVFSUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= Mn7rNVE{PTB7MUO=
B4B8 NILsc|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDtS40yODBibl2= M4nN[FczKGh? NEXyTpNFVVOR NGXBZ5hKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= MoC4NVE{PTB7MUO=
B7E3 NXro[Gk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfpNVAxKG6P NV7GXXNNPzJiaB?= M2\TN2ROW09? NWG0[ZBmUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= NWOwS5hpOTF|NUC5NVM>
UM-SCC-9 MkToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfLdWIyODBibl2= M2jjZ|czKGh? MVHEUXNQ NV7veFNCUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= NF:2[4QyOTN3MEmxNy=>
UM-SCC-11B MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHuO5MyODBibl2= NXHzbFhrPzJiaB?= M3TGOGROW09? NWTYZXd4UW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= NY\VdoVYOTF|NUC5NVM>
H460 M3G4T2Z2dmO2aX;uJGF{e2G7 MV[xNEDPxE1? NY\Q[IkyOjRiaB?= MUjEUXNQ MkXGTY5lfWOnczDCZ4wuOiCyaH;zdIhwenmuYYTpc44h[W6mIHPs[YF3[WenIHPvdpJmdGG2ZXSge4l1cCCJMj3NJJBp[XOnIHHydoV{fA>? MUKxNlQ6OjFzNx?=
U266 NW\FWJc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrVUnQ2ODBibnevcYw> M2PBS|Q5KGh? NFnqT4NFVVOR Mni1TY5pcWKrdIOgZ4VtdCCpcn;3eIg> MV2xNlY{OTZzOR?=
ARH77 NWWyV5p7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHxTmdnPTByIH7nM41t MonjOFghcA>? M13pOWROW09? NGm1S2FKdmirYnn0d{Bk\WyuIHfyc5d1cA>? MkfTNVI3OzF4MUm=
WAD-1 M2DXU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHpWWc2ODBibnevcYw> NY\Cd2NnPDhiaB?= NXW4ZolxTE2VTx?= NH3aT2pKdmirYnn0d{Bk\WyuIHfyc5d1cA>? MUOxNlY{OTZzOR?=
U266/LR7 MmDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\OOVAxKG6pL33s MkXaOFghcA>? MU\EUXNQ NV[w[4JXUW6qaXLpeJMh[2WubDDndo94fGh? NUHi[ZJFOTJ4M{G2NVk>
U266/dox4 MnjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV61NFAhdmdxbXy= NX30dFdsPDhiaB?= Ml\nSG1UVw>? MVXJcohq[mm2czDj[YxtKGe{b4f0bC=> Mn25NVI3OzF4MUm=
RPMI8226/LR5 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHX4bGg2ODBibnevcYw> MWK0PEBp NWHH[HRbTE2VTx?= M4XiRmlvcGmkaYTzJINmdGxiZ4Lve5Rp MmXDNVI3OzF4MUm=
H460 M4niZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn30NVAh|ryP M2jBUlczKGh? MV;EUXNQ MYrJR|UxRTFyMDDuUS=> MYixNlY{OTZ{MB?=
H358 NGr2WlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVKxNEDPxE1? NFzKNGg4OiCq M{PiOmROW09? NWTYTXh1UUN3ME23NEBvVQ>? NV\obpF1OTJ4M{G2NlA>
H322 MmTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLaNVAh|ryP M2jJcFczKGh? MWjEUXNQ M2DXNGlEPTB;NkKwJI5O NYfvOIRGOTJ4M{G2NlA>
H460 Mn2wSpVv[3Srb36gRZN{[Xl? MWSxNFAhdk1? M{S5NlI1KGh? NUHYT|BJTE2VTx?= MonJTY5lfWOnczDHNk1ONXCqYYPlJIFzemW|dDDhcoQhfHWkdXzpckBie3OnbXLsfU1lcXOjc4PlcYJtgQ>? Mmf5NVI3OzF4MkC=
LNCap-Pro5 NF;DcXdHfW6ldHnvckBCe3OjeR?= NHS0WIIyKM7:TR?= NVjoeI1uPCCq M3\XPWROW09? MkDUV5Ri[mmuaYrld{BxPTN? NV[ze4F3OTR4MUK1N|I>
T29 NVLsOlBCSXCxcITvd4l{KEG|c3H5 M3Pme|UxKG6P MnfNOFghcCB? NYXScnNnTE2VTx?= NFfLUoFKdmS3Y3XzJINmdGxiYYDvdJRwe2m| NXqxOGhuOTZ5N{ixO|k>
T29Kt1 MX3BdI9xfG:|aYOgRZN{[Xl? M2riflUxKG6P NX\aTWMyPDhiaDC= MlXCSG1UVw>? MWTJcoR2[2W|IHPlcIwh[XCxcITvd4l{ M4fHRVE3Pzd6MUe5
HCT116 MoHZRZBweHSxc3nzJGF{e2G7 MnTkOVAhdk1? NXnOcodPPDhiaDC= MkfiSG1UVw>? MnTxTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NFXoepYyPjd5OEG3PS=>
HKe-3 NWTCN3hVSXCxcITvd4l{KEG|c3H5 MVS1NEBvVQ>? MlzFOFghcCB? NVLLUnp7TE2VTx?= NEW2XGdKdmS3Y3XzJINmdGxiYYDvdJRwe2m| NYTyfop4OTZ5N{ixO|k>
NB-1691 Ml3iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGD4fFkyKM7:TR?= NVfxbZN6PzJiaB?= M4HY[GlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckB1dyB3JR?= M1XLOFE4Pjh7Nki0
CHLA-255 NFfxd4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjVbWVIOSEQvF2= NE\qeWs4OiCq M3vSdWlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckB1dyB{JR?= MXyxO|Y5QTZ6NB?=
SK-N-AS MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\jSpIyKM7:TR?= NFvGbJE4OiCq MWnJcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36geI8hOTBn NUm4e3BqOTd4OEm2PFQ>
NB-1691 NVXmOZJDTnWwY4Tpc44hSXO|YYm= NHXYfYQyOCCwTR?= NFy2eWIzPCCq M3\YdnNq\26rZnnjZY51dHlicnXkeYNmeyClZXzsd{BqdiC2aHWgS|AwTzFicHjhd4U> NXfnfnMyOTd4OEm2PFQ>
CHLA-255 NIXvfldHfW6ldHnvckBCe3OjeR?= MYWxNEBvVQ>? MXKyOEBp M4\0WG1w\GW|dHz5JJJm\HWlZYOgZ4VtdHNiaX6geIhmKEdyL1exJJBp[XOn MYOxO|Y5QTZ6NB?=
RPMI 8226 NEXzbVBHfW6ldHnvckBCe3OjeR?= M2Hse|IxKG6P NHHPdYo5KGh? NH3xVmpUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? NIjn[o8yQTR|NkC1NC=>
MM.1S MoPSSpVv[3Srb36gRZN{[Xl? MkXjNlAhdk1? MVW4JIg> NWPab3IyW2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl? MlzENVk1OzZyNUC=
U266 MnvlSpVv[3Srb36gRZN{[Xl? MXWyNEBvVQ>? M3XOSVghcA>? NXHHXGJ5W2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl? NFTYPFkyQTR|NkC1NC=>
OPM1 NELTcYRHfW6ldHnvckBCe3OjeR?= MmHJNlAhdk1? MX:4JIg> NG\aWXVUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? M2m3b|E6PDN4MEWw
INA6 MnnoSpVv[3Srb36gRZN{[Xl? NIK0bJAzOCCwTR?= MXu4JIg> M3iw[3Nq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 NVnGSIxHOTl2M{[wOVA>
OPM2 NYPMXpM6TnWwY4Tpc44hSXO|YYm= MU[yNEBvVQ>? NUW4fpdWQCCq NYm4NVZZW2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl? M2jSd|E6PDN4MEWw
RPMI 8226 NECzc4lHfW6ldHnvckBCe3OjeR?= MUSyNEBvVQ>? M{DHVVghcA>? MYjJcoR2[2W|IFTORUB{gW62aHXzbZM> MVexPVQ{PjB3MB?=
BaF/3 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUCxNFAhdk1? NVrDUmZ1PDhiaB?= MV;JR|UxRTZwMjDuUS=> MUiyNFMxPTZ7Mh?=
BaF/3-p210 Ml3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fpSFExOCCwTR?= MoTJOFghcA>? NE\D[5NKSzVyPUSuO{BvVQ>? NVnSU49EOjB|MEW2PVI>
TCC-S NGnFXJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIH0fVYyODBibl2= MXK0PEBp M1L1bGlEPTB;Mj64JI5O M2PlXFIxOzB3Nkmy
BaF/3 MUXGeY5kfGmxbjDBd5NigQ>? NID4c4M3KG6P NYPPbVh7PDhiaB?= NWL5RpdRUW6mdXPld{BiKGe{ZXH0JGcyKGOnbHytZ5lkdGViYYLy[ZN1 M2rzTlIxOzB3Nkmy
BaF/3-p210 MWfGeY5kfGmxbjDBd5NigQ>? NVHwN5JIPiCwTR?= NWS1NHhkPDhiaB?= MVLJcoR2[2W|IHGgd4xq\2i2IFexJINmdGxvY4njcIUh[XK{ZYP0 MkXiNlA{ODV4OUK=
BaF/3-p210 MWHGeY5kfGmxbjDBd5NigQ>? M3u0dFYhdk1? NH\SXWozPCCq NHnkdVlT\WS3Y3XzJJRp\SCyaH;zdIhwenmuYYTpc44h[W6mIITo[UBi[3Srdnn0fUBw\iCUYh?= MV[yNFMxPTZ7Mh?=
Raji NHXsdFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3WyZ|Eh|ryP NYXVfnBkOjRiaB?= NHuxbWpT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= M4Dm[lIyOTdyOUi4
LCL-1 NEP3VZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHGVlZlOSEQvF2= NH;SdYEzPCCq Mof1VoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi MYeyNVE4ODl6OB?=
LCL-2 NXvSdmd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWixJO69VQ>? NHTiW|IzPCCq NH\nUpNT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= NVj3RWIzOjFzN{C5PFg>
BJAB NY[xPGppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfNNUDPxE1? NV\BOWhyOjRiaB?= M3TQbXJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= MXeyNVE4ODl6OB?=
SNT-13 MnLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvMNUDPxE1? M4PURlI1KGh? NGL5W2dT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= MmfrNlEyPzB7OEi=
SNT-16 MnvhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmntNUDPxE1? NVn5UZJHOjRiaB?= M{PDSnJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= NX22PGRYOjFzN{C5PFg>
Jurkat MkixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH21TFYyKM7:TR?= Mm\VNlQhcA>? NEXpPGRT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= NW\tXVF1OjFzN{C5PFg>
KAI-3 NYjpO21rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\ZNUDPxE1? M1rCNVI1KGh? MojlVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi NIjTWIQzOTF5MEm4PC=>
SNK-6 Mo[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnnSIpSOSEQvF2= NFjvUpczPCCq MnfJVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi NFzsbHczOTF5MEm4PC=>
KHYG-1 Mmj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHqUogyKM7:TR?= NV36ZW41OjRiaB?= M1Tyd3Jm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= NGDXNWEzOTF5MEm4PC=>
SNT-16 NFHWb|FCeG:ydH;zbZMhSXO|YYm= M3Pye|Eh|ryP NY[xdI9[PiCq NHXNUlJKdmS3Y3XzJINmdGxiYYDvdJRwe2m| NVjncJluOjFzN{C5PFg>
Jurkat MVnBdI9xfG:|aYOgRZN{[Xl? MY[xJO69VQ>? Mn\VOkBp NUO5cGRXUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NGTCXJQzOTF5MEm4PC=>
KAI-3 NYD1b3VsSXCxcITvd4l{KEG|c3H5 NV;FXI5wOSEQvF2= M{DsRVYhcA>? M4G0c2lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NWP2OVh6OjFzN{C5PFg>
KHYG-1 MnvNRZBweHSxc3nzJGF{e2G7 NX;YTWQ5OSEQvF2= NWn6dIY1PiCq MYXJcoR2[2W|IHPlcIwh[XCxcITvd4l{ MoqzNlEyPzB7OEi=
SNT-13 MoS2RY51cX[rcnHsJGF{e2G7 MVOxJO69VQ>? Ml2wNlQhcA>? M3\EUGlv\HWlZYOgcJl1cWNiaX7m[YN1cW:wIH;mJGVDXg>? MX2yNVE4ODl6OB?=
SNT-16 M{PKfmFvfGm4aYLhcEBCe3OjeR?= NUD2eINzOSEQvF2= NF3NOVAzPCCq NG\PN49KdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ? MlTRNlEyPzB7OEi=
KAI-3 NUGydHp[SW62aY\pdoFtKEG|c3H5 M3f0TFEh|ryP MU[yOEBp MkDtTY5lfWOnczDsfZRq[yCrbn\lZ5Rqd25ib3[gSWJX M4rBOFIyOTdyOUi4
SNK-6 M{C1[2FvfGm4aYLhcEBCe3OjeR?= M{LTSFEh|ryP M{\kd|I1KGh? NUDpeWZ7UW6mdXPld{BtgXSrYzDpcoZm[3Srb36gc4YhTUKY MX2yNVE4ODl6OB?=
RAW 264.7 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYGxNFAhdk1? NVfsS4hyPDhiaB?= NYmzVoFVWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg MkXENlI1OjdzNUS=
A375 NV3DNFV5SXCxcITvd4l{KEG|c3H5 MVyxNEBvVQ>? MX6yOEBp NIDBbJlKdmS3Y3XzJINmdGxiYYDvdJRwe2m| MWWyN|A4QTB6Mx?=
BLM Mmf6RZBweHSxc3nzJGF{e2G7 MX6xNEBvVQ>? M13XVVI1KGh? NVvqTFBzUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MmnnNlMxPzlyOEO=
A375 M2rHZmF2fG:yaHHnfUBCe3OjeR?= NXSxRYJYOTBibl2= M3O2W|EzKGh? NWfrU2dmUW6mdXPld{Bnd3KvYYTpc44hd2ZiYYX0c5Bp[Wexc3;t[ZM> MmnMNlMxPzlyOEO=
BLM M17yb2F2fG:yaHHnfUBCe3OjeR?= NFjoeXIyOCCwTR?= MoTKNVIhcA>? NX3BSWNwUW6mdXPld{Bnd3KvYYTpc44hd2ZiYYX0c5Bp[Wexc3;t[ZM> NIrPOYEzOzB5OUC4Ny=>
H1299 NWDac|JKSXCxcITvd4l{KEG|c3H5 MWi4NEBvVQ>? NYfuN|VnOjRiaB?= NH7kcIRFVVOR MUPT[Y5{cXSrenXzJG5US0yFIHPlcIx{KHSxIF3TR{1l\XKrdnXkJIlEQS2rbnT1Z4VlKGGyb4D0c5Nqew>? MnvvNlU{OjN4OUO=
Hut-78 NVrTPIFCTnWwY4Tpc44hSXO|YYm= NIm5[4MyODBibl2= NEPrb2IzPCCq Mmi0SG1UVw>? M4ewbWRwf26{ZXf1cIF1\XNiVFfGMe6zOSCjbnSgTWwuOTBiZYjwdoV{e2mxbh?= MkiyNlU3QDF|M{W=
H9 MYXGeY5kfGmxbjDBd5NigQ>? MX[xNFAhdk1? MWqyOEBp MUPEUXNQ MlLySI94dnKnZ4XsZZRmeyCWR1[t{tIyKGGwZDDJUE0yOSCneIDy[ZN{cW:w Mn\DNlU3QDF|M{W=
HH NUH1[3h4TnWwY4Tpc44hSXO|YYm= MXuxNFAhdk1? MmHQNlQhcA>? MmG2SG1UVw>? MlO5[I94dnKnZ4XsZZRmeyCWR1[t{tIyKGGwZDDJUE0yOiCneIDy[ZN{cW:w NUPicIN3OjV4OEGzN|U>
Hut-78 MojiUYloemG2aX;uJGF{e2G7 M3vVR|ExOCCwTR?= NUf3N2k4OjRiaB?= NGfOTlhFVVOR NGPuXJpT\WS3Y3XzJINmdGxibXnndoF1cW:wIHL5JFgx6oDVOUCl MWeyOVY5OTN|NR?=
HH NXTncVI{VWmpcnH0bY9vKEG|c3H5 NIfCR|kyODBibl2= M{XQSlI1KGh? NUHLOXY2TE2VTx?= NXnoOG9HWmWmdXPld{Bk\WyuIH3p[5JifGmxbjDifUA5OOLCk{mxKS=> M2rTSFI2PjhzM{O1
U937 NH6yU25HfW6ldHnvckBCe3OjeR?= MYmxNFAhdk1? NWXLO3dNPiCq Mlr5TY5lfWOnczDJUE05KGW6cILld5Nqd25iaX6gUHBUNXO2aX31cIF1\WRiVUmzO{Bu[WO{b4DoZYdmew>? M{exNlI2PzlzNEe3
human PBMC M3jV[GZ2dmO2aX;uJGF{e2G7 MmGzNVAxKG6P Mk[4NlQhcA>? MUHJcoR2[2W|IFnMMVghemWuZXHz[S=> NXy1PGJTOjV5OUG0O|c>
ES6 MnTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTBwMECyNUBvVQ>? MkLqV2FPT0WU
SK-UT-1 M1LMTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfuZpJKUUN3ME2wMlE3OyCwTR?= NWLB[o9OW0GQR1XS
SH-4 NVHkT|ZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTjTWM2OD1yLkG3N{BvVQ>? NEfFW2NUSU6JRWK=
TE-9 MoDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTBwMUiyJI5O Mmm1V2FPT0WU
A253 NWnldlJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvjRY9oUUN3ME2wMlIxQCCwTR?= MYrTRW5ITVJ?
no-10 NWq4OGpWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInBUVFKSzVyPUCuNlEhdk1? NYL6TmpvW0GQR1XS
MMAC-SF MlTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIH3RWRKSzVyPUCuNlE3KG6P NHrSPXRUSU6JRWK=
A101D MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVSxclJYUUN3ME2wMlIzPSCwTR?= MVjTRW5ITVJ?
NTERA-S-cl-D1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTBwMkSzJI5O MVfTRW5ITVJ?
8-MG-BA Mn;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo[yTWM2OD1yLkK1JI5O NFvqOXhUSU6JRWK=
KNS-42 NVi3VIZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\5PXRKSzVyPUCuNlU5KG6P MlvMV2FPT0WU
LXF-289 NFTQUYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTBwMk[5JI5O NXGwOXBtW0GQR1XS
OVCAR-4 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;5cmlEPTB;MD6yPFkhdk1? NWTwTWc3W0GQR1XS
LOUCY M1fvNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTU[3NbUUN3ME2wMlI6OyCwTR?= NVHsPVNDW0GQR1XS
BB65-RCC NY\sSWlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwM{C0JI5O M373RXNCVkeHUh?=
D-542MG M3zVUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk[1TWM2OD1yLkOyPUBvVQ>? M3W4WHNCVkeHUh?=
ONS-76 Mlf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnOwTWM2OD1yLkOzJI5O NWrFeFR1W0GQR1XS
BB30-HNC NEfhXoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH:1T29KSzVyPUCuN|M2KG6P MUPTRW5ITVJ?
KS-1 MkjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\meWlKSzVyPUCuN|Qhdk1? M3fLdXNCVkeHUh?=
A388 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnz2TWM2OD1yLkO1OkBvVQ>? MW\TRW5ITVJ?
ES8 NIfk[lFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTBwNDDuUS=> MWPTRW5ITVJ?
MZ2-MEL NHPXdpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjYc3lKSzVyPUCuOFA4KG6P NUnLfWp{W0GQR1XS
HCC2998 NIfGSHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPVTWM2OD1yLkSxNkBvVQ>? NEjaWmdUSU6JRWK=
D-247MG NVH6TnpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTBwNEGzJI5O NX\ucoFNW0GQR1XS
ACN NYDWe4dZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXyyUXNPUUN3ME2wMlQyPyCwTR?= MUjTRW5ITVJ?
LB2518-MEL M3;MVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvJcXdKSzVyPUCuOFI2KG6P MnLHV2FPT0WU
ES1 NG\tOZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTBwNEOgcm0> NE\ibmlUSU6JRWK=
HCE-T NHrTTWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYG2UZBmUUN3ME2wMlQ{QSCwTR?= MnPCV2FPT0WU
OS-RC-2 MnzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnDUlVKSzVyPUCuOFQhdk1? NFq5ZXJUSU6JRWK=
MFH-ino NYPJPFlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\URmlEPTB;MD60OFMhdk1? MmixV2FPT0WU
OCUB-M MmXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULONpZQUUN3ME2wMlQ1PyCwTR?= Mle2V2FPT0WU
CP66-MEL Mk\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTBwNEezJI5O NX3MW2tbW0GQR1XS
LB771-HNC NH3vSWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTBwNEe0JI5O MorTV2FPT0WU
DSH1 M1zQd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnHOFByUUN3ME2wMlQ5KG6P NX3lWGRDW0GQR1XS
HUTU-80 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoKwTWM2OD1yLkWzN{BvVQ>? Mlz1V2FPT0WU
CESS NGHU[3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PH[mlEPTB;MD61N|ghdk1? M4\ucnNCVkeHUh?=
NCI-H747 NG\KflJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTBwNUO5JI5O MlrVV2FPT0WU
HT-144 MoTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXyzUIlUUUN3ME2wMlU4PiCwTR?= NXiwUWs2W0GQR1XS
COLO-829 MlqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TBcWlEPTB;MD62NVQhdk1? NVX3OHhqW0GQR1XS
A4-Fuk NHK4WVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2D6V2lEPTB;MD62NlMhdk1? MmXjV2FPT0WU
GI-ME-N MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTBwNkO0JI5O MmGwV2FPT0WU
LB831-BLC NXm3eok4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3u0ZWlEPTB;MD62OFEhdk1? MlW5V2FPT0WU
HOP-62 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3z6UmlEPTB;MD62OFchdk1? M13acHNCVkeHUh?=
BB49-HNC MmPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjlU3VKSzVyPUCuOlUzKG6P MVnTRW5ITVJ?
D-336MG MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVmyOG9CUUN3ME2wMlY2PyCwTR?= NFftb|RUSU6JRWK=
TK10 M4fRSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDRTWM2OD1yLk[3PUBvVQ>? MmLvV2FPT0WU
Ramos-2G6-4C10 NFvUeWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm[0TWM2OD1yLk[5N{BvVQ>? MoDNV2FPT0WU
LB373-MEL-D NYLJeHNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TZTmlEPTB;MD63JI5O M4jhS3NCVkeHUh?=
SF126 NXn3fmtzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rQbmlEPTB;MD63NFEhdk1? M{i3XHNCVkeHUh?=
UACC-257 NYXFPVJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXaco1KSzVyPUCuO|Ehdk1? M1HTT3NCVkeHUh?=
KINGS-1 MlyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkS1TWM2OD1yLkeyNkBvVQ>? M2fOR3NCVkeHUh?=
LS-513 M3yyPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\qTYVXUUN3ME2wMlc{QSCwTR?= MVjTRW5ITVJ?
GI-1 MlfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHtVW5bUUN3ME2wMlc3PCCwTR?= NFjvemlUSU6JRWK=
ES7 NFjNbohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjWTWM2OD1yLke2OkBvVQ>? Mnj2V2FPT0WU
LB2241-RCC NFryWohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUf4OIduUUN3ME2wMlgxPCCwTR?= MkTFV2FPT0WU
D-263MG NFvnSplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHYfFRPUUN3ME2wMlgxPyCwTR?= MoLGV2FPT0WU
SW684 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDYTWM2OD1yLkiyNUBvVQ>? NI\De5hUSU6JRWK=
ML-2 MmHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTBwOEKxJI5O NYqyXIljW0GQR1XS
SK-LMS-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHkdpVKSzVyPUCuPFU1KG6P NIC2dJZUSU6JRWK=
TE-5 Mk\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrNRYNIUUN3ME2wMlg3PSCwTR?= NILicINUSU6JRWK=
QIMR-WIL NWnN[5BNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXi[5dPUUN3ME2wMlg5QSCwTR?= MUjTRW5ITVJ?
NCI-H1355 NInFRYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjITWM2OD1yLki5OUBvVQ>? NXXh[FQ6W0GQR1XS
SNB75 MnzjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTBwOUGyJI5O MXPTRW5ITVJ?
RXF393 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLodVRIUUN3ME2wMlkyPCCwTR?= M3nmdHNCVkeHUh?=
IST-MEL1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXvN2E5UUN3ME2wMlkyPyCwTR?= NFjaeINUSU6JRWK=
SF268 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnSbWNKSzVyPUCuPVI{KG6P M2jVbnNCVkeHUh?=
KALS-1 NVnQSoJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTBwOUK1JI5O NXzIb4w3W0GQR1XS
HC-1 M2HrRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTBwOUe1JI5O M2HqOXNCVkeHUh?=
SW872 NF3tN2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTBwOUm2JI5O MmT4V2FPT0WU
PSN1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTMRoVKSzVyPUGuNFEhdk1? M3vJenNCVkeHUh?=
TE-1 M2LSdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFuxNIxKSzVyPUGuNFMhdk1? M4HDWnNCVkeHUh?=
TE-10 M{[4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3[xUGlEPTB;MT6wN{BvVQ>? MXLTRW5ITVJ?
RKO M4TMfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTFwME[gcm0> MX\TRW5ITVJ?
LC-2-ad M3foR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPHR2JKSzVyPUGuNFghdk1? NHrtVJFUSU6JRWK=
SK-MM-2 NIDEZ5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWro[mY6UUN3ME2xMlA6KG6P NEHmR5dUSU6JRWK=
VA-ES-BJ MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\FTWM2OD1zLkC5JI5O NUKz[ZUyW0GQR1XS
MZ7-mel NFuxO2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTOb5BoUUN3ME2xMlA6KG6P NVXC[HE4W0GQR1XS
D-392MG NUn6UI5DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULaXVdSUUN3ME2xMlEhdk1? M4P2dnNCVkeHUh?=
CCRF-CEM NF\QPG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTFwMUOgcm0> NWj5bZpIW0GQR1XS
EM-2 NETFeodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7lTWM2OD1zLkG2JI5O NWrkXWREW0GQR1XS
HAL-01 MlLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;3dmlEPTB;MT6xPEBvVQ>? M33DTXNCVkeHUh?=
TE-8 NEHUemlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoX6TWM2OD1zLkG5JI5O M4\zUHNCVkeHUh?=
NCI-H1882 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTFwMjDuUS=> M4DrTnNCVkeHUh?=
Daudi NIK3SJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTFwMkKgcm0> NEL5fHpUSU6JRWK=
BL-41 Mlj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TtXmlEPTB;MT6yOUBvVQ>? NHu5ZXBUSU6JRWK=
SR M1nSNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{H0UmlEPTB;MT6yOUBvVQ>? MmHiV2FPT0WU
KM12 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XrVGlEPTB;MT6yO{BvVQ>? NE\mWpFUSU6JRWK=
K5 NWDmfVhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXhTWM2OD1zLkK4JI5O MV7TRW5ITVJ?
A3-KAW M17mbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTFwMkigcm0> NXzxWlVEW0GQR1XS
CMK MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTFwMkmgcm0> M2XLRnNCVkeHUh?=
Calu-6 NGTZeWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlOxTWM2OD1zLkK5JI5O MnPDV2FPT0WU
IST-SL2 NIP6OFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\LTIRKSzVyPUGuN|Ehdk1? M1r2fXNCVkeHUh?=
OPM-2 MoK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTFwM{Ogcm0> Mn7SV2FPT0WU
DU-4475 MoLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrqco5wUUN3ME2xMlM3KG6P NIDZ[IlUSU6JRWK=
ECC12 NH7iN2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDYfYlnUUN3ME2xMlM4KG6P NIW0[phUSU6JRWK=
L-540 M4jmPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXyU45KSzVyPUGuN|chdk1? NVP6RoVUW0GQR1XS
CAS-1 NGXPT3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvIXIdKSzVyPUGuN|chdk1? NILrSlNUSU6JRWK=
PF-382 NF\QbINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojBTWM2OD1zLkS3JI5O M3TtcnNCVkeHUh?=
LS-411N NXTi[FJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TwbGlEPTB;MT61N{BvVQ>? Ml7tV2FPT0WU
NCI-H69 NFLzdZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknOTWM2OD1zLkW0JI5O NWXsdoxsW0GQR1XS
NB12 M33tWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmP3TWM2OD1zLkW2JI5O MVvTRW5ITVJ?
HEL MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fNdGlEPTB;MT62NUBvVQ>? M4r1T3NCVkeHUh?=
GCIY MorTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfXd3ZYUUN3ME2xMlYzKG6P NXHkN5BLW0GQR1XS
EHEB M2DKVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnQTWM2OD1zLk[3JI5O NEfxNJVUSU6JRWK=
TGBC1TKB MmftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrXdYtjUUN3ME2xMlcyKG6P NID3Z4JUSU6JRWK=
KURAMOCHI MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnrcYpKSzVyPUGuO|Ihdk1? NYLoXpBEW0GQR1XS
U-266 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NECyemxKSzVyPUGuO|Yhdk1? M4TrPXNCVkeHUh?=
LC4-1 M{jCb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\sUIJKSzVyPUGuO|khdk1? M1\kV3NCVkeHUh?=
NCI-H2126 NELnVXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LIcmlEPTB;MT64JI5O NWrOOnc2W0GQR1XS
NCI-H1092 NXXBTVVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zRTWlEPTB;MT64JI5O NFXTeGdUSU6JRWK=
GB-1 NWPkclZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTFwOEGgcm0> MkizV2FPT0WU
MV-4-11 NXj6WnhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M161UGlEPTB;MT64NkBvVQ>? NY\DfY9JW0GQR1XS
Becker NWrHOVV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnme2JKSzVyPUGuPFMhdk1? M2PHPXNCVkeHUh?=
MPP-89 MoTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;qeWVKSzVyPUGuPFkhdk1? NWnp[pUxW0GQR1XS
BE-13 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTFwOUOgcm0> NHjrbXVUSU6JRWK=
697 MkK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTFwOUmgcm0> NYfSNW54W0GQR1XS
NKM-1 NXG0b4VRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fFOWlEPTB;MjDuUS=> MU\TRW5ITVJ?
NB13 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTJibl2= MUjTRW5ITVJ?
LS-123 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVO5[W41UUN3ME2yMlAzKG6P MYPTRW5ITVJ?
NB17 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fj[mlEPTB;Mj6wOEBvVQ>? NFLOSYNUSU6JRWK=
LAN-6 NIXaT2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1z2ZmlEPTB;Mj6wOUBvVQ>? M{i4NXNCVkeHUh?=
EW-24 NWnSRXJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvHe4NpUUN3ME2yMlA5KG6P MoPVV2FPT0WU
NOS-1 NYL5RpA2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnaTWM2OD1{LkGxJI5O MnP5V2FPT0WU
BL-70 MnHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTJwMUKgcm0> MX3TRW5ITVJ?
GT3TKB NYfRcVJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYK1R5J2UUN3ME2yMlEzKG6P MVrTRW5ITVJ?
HH NYjZXmF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;nXGlEPTB;Mj6xN{BvVQ>? MmjqV2FPT0WU
KE-37 NEixdHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfEfXZKSzVyPUKuNVMhdk1? NYLmfmNpW0GQR1XS
MOLT-4 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4W3cWlEPTB;Mj6xN{BvVQ>? NV3ZSVBrW0GQR1XS
EKVX MoewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13PTWlEPTB;Mj6xOEBvVQ>? NXXXOIdpW0GQR1XS
KGN MlvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\zR2lEPTB;Mj6xOUBvVQ>? MkL4V2FPT0WU
ES4 NX;2UW9jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3n5NmlEPTB;Mj6xOkBvVQ>? MVjTRW5ITVJ?
SJSA-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLpXHRKSzVyPUKuNlEhdk1? MX3TRW5ITVJ?
KMOE-2 NVzYZZZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrodVBRUUN3ME2yMlI{KG6P MV3TRW5ITVJ?
NB5 M1vqNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml:0TWM2OD1{LkK3JI5O MmXCV2FPT0WU
BC-1 NIHY[45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;E[|JKSzVyPUKuN|Ehdk1? MYHTRW5ITVJ?
NB10 MonHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTJwM{Kgcm0> NWH2VoVLW0GQR1XS
RPMI-8226 NF71WGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTJwM{Wgcm0> NW\yUmVbW0GQR1XS
SCC-3 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTJwM{egcm0> M4nMOXNCVkeHUh?=
ARH-77 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTJwM{igcm0> MXjTRW5ITVJ?
NCI-H748 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7aboRKSzVyPUKuN|khdk1? NI[3UJFUSU6JRWK=
KU812 NG\LcHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LEOWlEPTB;Mj60NkBvVQ>? MXfTRW5ITVJ?
NCI-H64 NVG3XFA5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTJwNESgcm0> M1XDb3NCVkeHUh?=
NB69 NWPrXVR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DESWlEPTB;Mj60OkBvVQ>? NHu1VoVUSU6JRWK=
KNS-81-FD M2PyNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XPfGlEPTB;Mj60PEBvVQ>? MWrTRW5ITVJ?
LB1047-RCC NHvrR29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTyTWM2OD1{LkW3JI5O M33CVHNCVkeHUh?=
EB-3 NFPj[YtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4KzT2lEPTB;Mj62OkBvVQ>? M3HUS3NCVkeHUh?=
Mo-T MmezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPj[W5KSzVyPUKuO|Qhdk1? MVvTRW5ITVJ?
EW-16 NEPPNXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nwSWlEPTB;Mj63OUBvVQ>? MUfTRW5ITVJ?
CTV-1 MkewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXxTWM2OD1{Lkigcm0> M{fWb3NCVkeHUh?=
ETK-1 MlLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPuTWM2OD1{Lki0JI5O MWDTRW5ITVJ?
C2BBe1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TsSmlEPTB;Mj64PUBvVQ>? MYDTRW5ITVJ?
MOLT-16 NHzH[XZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTJwOEmgcm0> NITOeoVUSU6JRWK=
SW954 NIT5NGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTxTWM2OD1{Lkmgcm0> NIHxS3VUSU6JRWK=
HT MnfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHi4NlhKSzVyPUOuNFIhdk1? NXnZdmxFW0GQR1XS
KARPAS-299 NFn2O2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfMcmdWUUN3ME2zMlA3KG6P NFHrPZlUSU6JRWK=
MONO-MAC-6 MmfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1q5eWlEPTB;Mz6xJI5O M4f0VXNCVkeHUh?=
CGTH-W-1 M3LZUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTNwMTDuUS=> MmXGV2FPT0WU
SK-PN-DW NFrCcYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTB[JlKSzVyPUOuNVQhdk1? NYjKRpVGW0GQR1XS
CW-2 M4Dh[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHjdZJKUUN3ME2zMlIyKG6P MVnTRW5ITVJ?
SK-N-DZ NX;BSWVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1S1WmlEPTB;Mz6yOkBvVQ>? NEXMNGJUSU6JRWK=
NEC8 NE\0e5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPxclRKSzVyPUOuN|Uhdk1? MkjsV2FPT0WU
LB996-RCC NU\pTIRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;ye2lEPTB;Mz60JI5O NWXhOoNsW0GQR1XS
DB Mlf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH23WWhKSzVyPUOuOFEhdk1? Mni0V2FPT0WU
TE-15 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHNTWM2OD1|LkSzJI5O NVq1WFNEW0GQR1XS
COR-L88 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkf5TWM2OD1|LkS3JI5O MmHSV2FPT0WU
LAMA-84 M3q2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTNwNEmgcm0> M3n0c3NCVkeHUh?=
MEG-01 M3y2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXiUnhkUUN3ME2zMlQ6KG6P MkPNV2FPT0WU
LOXIMVI NFvnZWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHqzU3JKSzVyPUOuOUBvVQ>? NE\UVZlUSU6JRWK=
RPMI-8402 M2HRdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTNwNTDuUS=> M4\XOXNCVkeHUh?=
KARPAS-45 Mn\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DBcmlEPTB;Mz61OEBvVQ>? NFm1cWVUSU6JRWK=
HCC1187 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoO1TWM2OD1|LkW0JI5O NUXZZ3E{W0GQR1XS
MZ1-PC NEXTUplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTnWJI4UUN3ME2zMlU1KG6P MYnTRW5ITVJ?
no-11 NW[4OFFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIK3TmlKSzVyPUOuOVUhdk1? MkPGV2FPT0WU
EVSA-T MmfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfUXWdKSzVyPUOuOkBvVQ>? NHnxe|dUSU6JRWK=
DJM-1 NF6xV2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHvd492UUN3ME2zMlY{KG6P MVfTRW5ITVJ?
COLO-684 NEfvdoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTNwNk[gcm0> MULTRW5ITVJ?
NMC-G1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWj3Nm5UUUN3ME2zMlY5KG6P MnXNV2FPT0WU
LC-1F NEnKOHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojRTWM2OD1|Lke0JI5O M3fl[XNCVkeHUh?=
RL95-2 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXYTWM2OD1|Lke5JI5O MVLTRW5ITVJ?
COLO-320-HSR NG\wRXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\HTWM2OD1|LkmyJI5O NVrWTGhkW0GQR1XS
RCC10RGB M1jHVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFr4TXlKSzVyPUOuPVMhdk1? NVnYVnV{W0GQR1XS
HD-MY-Z MoKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonNTWM2OD1|LkmzJI5O MnzmV2FPT0WU
NCI-H2141 NX22fIkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTRwMEWgcm0> MUjTRW5ITVJ?
K-562 MlXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTRwMUKgcm0> NIq2N5pUSU6JRWK=
NCI-H1648 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILaWldKSzVyPUSuNVMhdk1? NYfKfYUzW0GQR1XS
OMC-1 MnTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTRwMUigcm0> M3q0bXNCVkeHUh?=
LB647-SCLC NWPUPXhuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTRwMkKgcm0> M{Gx[3NCVkeHUh?=
TE-12 M{LQXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXThTZNzUUN3ME20MlI2KG6P NV3lR2lXW0GQR1XS
NOMO-1 M3u0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDoXWtKSzVyPUSuN|Mhdk1? M3Xmb3NCVkeHUh?=
Raji NUTONoZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTRwNE[gcm0> NVrwbJEzW0GQR1XS
NALM-6 NYjrOpJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTRwNEmgcm0> M4foTXNCVkeHUh?=
HL-60 NVL6RoptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7t[Jp2UUN3ME20MlY4KG6P NF3xWIhUSU6JRWK=
IST-SL1 MkiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3zRZpKSzVyPUSuOlghdk1? MXjTRW5ITVJ?
MHH-PREB-1 NGjJdXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTRwOE[gcm0> M2TBN3NCVkeHUh?=
MHH-NB-11 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFK3XGhKSzVyPUSuPVEhdk1? M3;wXXNCVkeHUh?=
JiyoyeP-2003 NELPNm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILDXYZKSzVyPUWgcm0> NI[1XppUSU6JRWK=
SBC-1 NU[2TXdFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XZbGlEPTB;NT6wNUBvVQ>? NEfRXINUSU6JRWK=
CHP-126 MlfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTRdodrUUN3ME21MlA3KG6P MXPTRW5ITVJ?
LU-139 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXKU5lpUUN3ME21MlE{KG6P NUjOc3kxW0GQR1XS
NCI-SNU-5 M{PmSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13nNGlEPTB;NT6xO{BvVQ>? MXzTRW5ITVJ?
SW962 M2naXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTVwMkGgcm0> NFzib3pUSU6JRWK=
EW-1 NI\IZVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlH2TWM2OD13LkOxJI5O NYHtNGVnW0GQR1XS
NCI-H1417 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUH2ZWNxUUN3ME21MlUyKG6P MXnTRW5ITVJ?
LU-65 M2eyVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF62O|hKSzVyPUWuPFQhdk1? NWrYTI5CW0GQR1XS
D-502MG M1G3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nt[2lEPTB;Nj6zO{BvVQ>? NW\0R2ZkW0GQR1XS
BC-3 Mk\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTZwNkGgcm0> NYLkd21NW0GQR1XS
GDM-1 NX;oTlVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjMe|ZnUUN3ME22Mlc4KG6P NXP2TJc3W0GQR1XS
NCI-H2196 NH\PfZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWGx[45yUUN3ME22Mlghdk1? M{XjWXNCVkeHUh?=
NB1 M{TueGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTZwOEigcm0> MXXTRW5ITVJ?
NCI-H345 NGDncYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELxTXFKSzVyPUeuNkBvVQ>? NWXx[JhrW0GQR1XS
SU-DHL-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfKW3RKSzVyPUeuNlQhdk1? NEXzfZpUSU6JRWK=
JVM-2 MkexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfEcYgxUUN3ME23MlI5KG6P NUfhUolYW0GQR1XS
LU-134-A MkLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjPW3pKSzVyPUeuN|khdk1? M1voV3NCVkeHUh?=
NCI-H1694 Mn;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnYTWM2OD15LkW4JI5O M4fPOnNCVkeHUh?=
NCI-SNU-16 NVfoNYs4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnISGVwUUN3ME23MlY2KG6P MVrTRW5ITVJ?
L-363 M37RNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTdwNzDuUS=> MUHTRW5ITVJ?
KG-1 M1zleGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnsTWM2OD15Lkm0JI5O MX3TRW5ITVJ?
MN-60 M4PZd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRThwMUSgcm0> M1W0[nNCVkeHUh?=
NB6 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRThwNEigcm0> NUPKVJc4W0GQR1XS
MLMA MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnOxTWM2OD16Lki1JI5O MXnTRW5ITVJ?
ATN-1 NIn0NZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DJemlEPTB;OD64PUBvVQ>? M3e5[3NCVkeHUh?=
SK-NEP-1 NWTUSmFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTlwMEGgcm0> M{HPWnNCVkeHUh?=
DMS-114 Mk\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3Lc4tIUUN3ME25MlYzKG6P NWjJbGI2W0GQR1XS
CTB-1 M1\Bcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;hRWlEPTB;OT62O{BvVQ>? NH3xXpBUSU6JRWK=
NCI-H2081 MlS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTFyLkC5JI5O NWXyd5BqW0GQR1XS
ES5 MoHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Xrd2lEPTB;MUCuN|ghdk1? MmPKV2FPT0WU
HCC1599 NYfKe5VDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPnfmF{UUN3ME2xNU46OSCwTR?= M1vuXnNCVkeHUh?=
NCI-H23 MnrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTF{LkGyJI5O NEHYNohUSU6JRWK=
NCI-H1581 MnXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEToeI1KSzVyPUGyMlI5KG6P M4PSOnNCVkeHUh?=
JVM-3 M37RZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHq1[YJKSzVyPUGyMlk6KG6P M4DkdnNCVkeHUh?=
NCI-SNU-1 MmPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWG4XGNPUUN3ME2xN{4yQSCwTR?= Mm\JV2FPT0WU
NB7 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2S3NmlEPTB;MUWuPVIhdk1? NYntTVY3W0GQR1XS
JAR NGL5TWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTHTWM2OD1zNj6xN{BvVQ>? MkHPV2FPT0WU
TGW MnLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYOySpY5UUN3ME2xOk41QCCwTR?= MnLkV2FPT0WU
U-87-MG NH3ITlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;ONmlEPTB;MU[uO|Yhdk1? NIDTc2JUSU6JRWK=
NCI-H1436 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfsZZNNUUN3ME2xO{4xOSCwTR?= NFvWdW1USU6JRWK=
GOTO NXnBXZJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTF5LkC2JI5O MkDUV2FPT0WU
COLO-800 NVrzWYRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTF5Lk[0JI5O NGnjOnJUSU6JRWK=
MFM-223 MojBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF65bWdKSzVyPUG3MlkyKG6P NFLt[21USU6JRWK=
EW-18 M37wUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NED3eVZKSzVyPUG3Mlk3KG6P NGrBOXhUSU6JRWK=
NB14 MnzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1y2fGlEPTB;MUeuPVghdk1? NE\POVNUSU6JRWK=
EB2 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXn0SXNTUUN3ME2xPE4xQCCwTR?= NHzlNZBUSU6JRWK=
EoL-1- MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3Zd295UUN3ME2xPE4{OSCwTR?= MYDTRW5ITVJ?
NCCIT NHXLe4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG[xWYdKSzVyPUG4MlM3KG6P MlrLV2FPT0WU
DG-75 M171bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIT4OFVKSzVyPUG4MlYyKG6P MmrPV2FPT0WU
HCC2218 NXX4eYZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLkRZdKUUN3ME2xPU42KG6P NHnlTolUSU6JRWK=
TE-6 Mn7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvxdY5KSzVyPUKwMlA5KG6P NVW1e|g5W0GQR1XS
SF539 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTJyLk[3JI5O MoDrV2FPT0WU
NCI-H446 Mlj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DpdmlEPTB;MkGuNVghdk1? NWfFSXU{W0GQR1XS
IST-MES1 NWflN3FxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXjPWRWUUN3ME2yNk44PyCwTR?= NXTQ[4V2W0GQR1XS
NCI-H82 NY\BXYpzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTJ|LkCyJI5O NV\FTXR4W0GQR1XS
HCC2157 M4nt[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHSycGFKSzVyPUKzMlE{KG6P NWLzSWpmW0GQR1XS
EW-12 NVjIdI94T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnETWM2OD1{Mz6xO{BvVQ>? MUfTRW5ITVJ?
SIMA NEXDTVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXu4bYNwUUN3ME2yN{4{QCCwTR?= MlXNV2FPT0WU
DOHH-2 NWXGdGxsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTJ|LkS1JI5O MYTTRW5ITVJ?
IM-9 NXf6SIc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPrS5FKSzVyPUKzMlU1KG6P M1nheXNCVkeHUh?=
EC-GI-10 NX2xOmxlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mki4TWM2OD1{ND6yN{BvVQ>? MoXMV2FPT0WU
HDLM-2 NHrIOlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\uTWM2OD1{ND61OEBvVQ>? MkOxV2FPT0WU
LS-1034 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonxTWM2OD1{NT63OUBvVQ>? NUftdpBlW0GQR1XS
REH NEmyb5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\ZXmlEPTB;Mk[uOFEhdk1? NIjuWnlUSU6JRWK=
LU-165 NUm4ZY1VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nJdWlEPTB;Mk[uO|Ihdk1? M{LNRXNCVkeHUh?=
NH-12 NYHNdYRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjX[4w3UUN3ME2yO{43PyCwTR?= NXj6ZXk2W0GQR1XS
WSU-NHL MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TMe2lEPTB;MkiuN|khdk1? NFrPXo9USU6JRWK=
ECC4 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnnN3BSUUN3ME2yPE44QSCwTR?= NIfZNlhUSU6JRWK=
OCI-AML2 NEHjT3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDzNWFKSzVyPUK5MlY6KG6P M3K5WHNCVkeHUh?=
EW-3 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDiSVZsUUN3ME2zNE42QSCwTR?= MonMV2FPT0WU
NCI-H526 MmrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfDcYNmUUN3ME2zNk42PCCwTR?= NVj0TFN3W0GQR1XS
NCI-H719 M17Mcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTN2LkOxJI5O NUPXUoFqW0GQR1XS
KARPAS-422 M1HTcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkS2TWM2OD1|NT6wOEBvVQ>? NVH0bFZWW0GQR1XS
SK-MEL-1 MlztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTN3LkG3JI5O NGjYVFVUSU6JRWK=
ES3 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVGxRpg5UUN3ME2zOU4yQSCwTR?= NWjlNJRCW0GQR1XS
UACC-812 NYe4S2VXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\GVnBKSzVyPUO1MlQ1KG6P MkLBV2FPT0WU
C8166 MnTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInJboZKSzVyPUO1Mlchdk1? M4TDTnNCVkeHUh?=
MDA-MB-134-VI MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnvTWM2OD1|NT64O{BvVQ>? Mof2V2FPT0WU
D-283MED M3Lsfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTN5Lke5JI5O NV;zcnV6W0GQR1XS
SHP-77 NGj5Z4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLKSWZrUUN3ME2zPE4xOyCwTR?= NUHxcY0yW0GQR1XS
NCI-H2227 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTRyLkS5JI5O MkHHV2FPT0WU
SKM-1 MnzIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTR{Lk[zJI5O NELId3dUSU6JRWK=
L-428 NWfSeopLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF6yVnVKSzVyPUSzMlg3KG6P MoraV2FPT0WU
RPMI-6666 Mnv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfFb2pKSzVyPUS1Mlg6KG6P MkG1V2FPT0WU
NCI-H716 NYLkSHJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfQOm5iUUN3ME20PE45OSCwTR?= NUiwO3NoW0GQR1XS
DMS-79 NV;2O4h4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTVyLkexJI5O NXT6W25JW0GQR1XS
RS4-11 NGWwVYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTVyLki4JI5O NGDCeJhUSU6JRWK=
NCI-H720 M2i2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\ucXFmUUN3ME21NU4yOSCwTR?= MUPTRW5ITVJ?
MC-CAR NWDQSHB{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTVzLkWyJI5O M3nIbnNCVkeHUh?=
TALL-1 NFnVT21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NET1UZBKSzVyPUWzMlkyKG6P NEixdW9USU6JRWK=
NCI-N87 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDTTmxSUUN3ME21OE4yQCCwTR?= NIjVfHlUSU6JRWK=
P30-OHK NV;OV3lnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXiXohKSzVyPUW0MlYyKG6P NGnnRphUSU6JRWK=
LP-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYr6UVlIUUN3ME22NU4zQCCwTR?= MYPTRW5ITVJ?
YT NX3a[JI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\1TWM2OD14MT64JI5O MmWzV2FPT0WU
MRK-nu-1 M{PudWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HOWmlEPTB;NkGuPFIhdk1? Mlr3V2FPT0WU
BT-474 NVyyOHFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1u0dGlEPTB;NkWgcm0> NVfBe45XW0GQR1XS
NCI-H322M MnTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTZ4LkGxJI5O NUXRSoZWW0GQR1XS
NCI-H128 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHKTJdKSzVyPUe0Mlc4KG6P NUHnToRXW0GQR1XS
KMS-12-PE NF7ZOZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk[1TWM2OD15Nj6yOEBvVQ>? MUTTRW5ITVJ?
KP-N-YS MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXu4N2Z4UUN3ME23Ok44PCCwTR?= NXL0b5VZW0GQR1XS
ALL-PO MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjGWYRsUUN3ME23O{43PiCwTR?= MY\TRW5ITVJ?
EW-13 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37oTGlEPTB;N{euO|Yhdk1? MUfTRW5ITVJ?
EW-11 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPzTWM2OD15OD61NkBvVQ>? NFK1R4JUSU6JRWK=
SK-N-FI NX;rTHhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnGbYtKSzVyPUiwMlIhdk1? MWjTRW5ITVJ?
CAL-148 NImxTGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHP0Oo9KSzVyPUixMlg1KG6P NVOzTHhMW0GQR1XS
RL MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPQ[GhKSzVyPUi2MlA6KG6P MUTTRW5ITVJ?
AM-38 NX;TRW5QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1L2WGlEPTB;OEiuNFghdk1? MXrTRW5ITVJ?
RH-1 M2XPcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHr[Y5KSzVyPUm5Mlg2KG6P MlLrV2FPT0WU
NCI-H1770 M3K3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\4PWlEPTB;MUCyMlQ6KG6P M1XNcHNCVkeHUh?=
SIG-M5 NYnTfG5IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;nXGlEPTB;MUC1MlA3KG6P NEHQZWZUSU6JRWK=
GR-ST M3X5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV:3bpVUUUN3ME2xNVMvOzRibl2= MmDqV2FPT0WU
ST486 NEDscmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\OTZlKSzVyPUGxOE4xPiCwTR?= M{XZOnNCVkeHUh?=
NCI-H1650 M2LlUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NViy[FRkUUN3ME2xNVUvOjlibl2= MYfTRW5ITVJ?
MHH-CALL-2 NWLPW3BpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnmNlJKSzVyPUGxOU44KG6P MYrTRW5ITVJ?
BV-173 M{jHVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEG2SoNKSzVyPUGyNk44OSCwTR?= MnLLV2FPT0WU
MC116 MlG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HNXGlEPTB;MUS4Mlg2KG6P MXHTRW5ITVJ?
NCI-H524 NYmzOVdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjSV41MUUN3ME2xOVkvOSCwTR?= NF6xZnBUSU6JRWK=
SCLC-21H MoDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;zWnVKSzVyPUG1PU41OSCwTR?= MXvTRW5ITVJ?
NCI-H1304 MkXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\NSlhWUUN3ME2xOlkvOjFibl2= NELGUWJUSU6JRWK=
NCI-H510A NHvYenlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXsUHZKSzVyPUG4OU4{PyCwTR?= NFPwSIFUSU6JRWK=
NCI-H209 M4nvfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PvdGlEPTB;MUm2MlUzKG6P MmLVV2FPT0WU
KM-H2 NU\1boF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nMcWlEPTB;MUm3MlA2KG6P NYrSfYRxW0GQR1XS
NCI-H1395 MlqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXzcZdKSzVyPUKxNE4yOyCwTR?= NHrOPHZUSU6JRWK=
NCI-H1155 NEXEcG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mon5TWM2OD1{M{CuN|Ihdk1? NVXmXI03W0GQR1XS
COR-L279 M{P6VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7pTWM2OD1{NUKuNVchdk1? M13m[3NCVkeHUh?=
NCI-H1299 M{fxV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTJ4MT63NUBvVQ>? M4\2SXNCVkeHUh?=
EW-22 NXrJXVBvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTJ4Mz63OUBvVQ>? MnPhV2FPT0WU
SK-MEL-2 Mn\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfwNo9KSzVyPUK4NU46KG6P NELhVFRUSU6JRWK=
KASUMI-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXH1T|liUUN3ME2yPFMvODVibl2= MlzZV2FPT0WU
NCI-H187 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlP4TWM2OD1{OEeuNFghdk1? M1LydHNCVkeHUh?=
NCI-H2171 MmLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTJ6OD65NkBvVQ>? MWfTRW5ITVJ?
LNCaP-Clone-FGC NH7KNlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTJ7NT6yOkBvVQ>? NWLNVGZrW0GQR1XS
NCI-H1522 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{SwO2lEPTB;M{C3MlA2KG6P NHXkWGxUSU6JRWK=
SCH NVnaS5YyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;VeZZvUUN3ME2zNlIvOjJibl2= MknFV2FPT0WU
THP-1 NVTiVGRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7MTWM2OD1|MkKuOkBvVQ>? MX\TRW5ITVJ?
SNU-C1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTN4Mj6wPUBvVQ>? MmnLV2FPT0WU
CA46 NHHMVFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\zXHpKSzVyPUO3N{43OyCwTR?= NH3HR21USU6JRWK=
NCI-H1963 NEjhT4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;pfHpKSzVyPUO4Ok4yQSCwTR?= NGDrR4hUSU6JRWK=
DEL M164T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPhZ2pKSzVyPUO5NU4zPyCwTR?= NHLqbpJUSU6JRWK=
TUR M{HHcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTN7Nj62NUBvVQ>? MXjTRW5ITVJ?
NCI-H226 MkjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HwUmlEPTB;NECzMlI{KG6P NUXCWXpCW0GQR1XS
COLO-668 M1jSfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTRyMz61O{BvVQ>? Ml31V2FPT0WU
CPC-N NIjFXWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XyOWlEPTB;NECzMlc4KG6P NWnCZYFXW0GQR1XS
NCI-H889 Mn[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TaNWlEPTB;NE[xMlkzKG6P M3XJXXNCVkeHUh?=
J-RT3-T3-5 M17MdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonQTWM2OD13M{KuOVchdk1? MUPTRW5ITVJ?
MSTO-211H NF64R3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fydmlEPTB;NUe0MlI3KG6P NYS4cZlmW0GQR1XS
SCC-15 Mmq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\mTWM2OD14NkeuOFchdk1? NHLpXlNUSU6JRWK=
SUP-T1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPrTo01UUN3ME22PFYvODRibl2= MUjTRW5ITVJ?
DMS-153 NIHJSVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXsPGVKSzVyPUe0Ok45OyCwTR?= NFPQS5BUSU6JRWK=
MS-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDUfnhKSzVyPUe1PU41OiCwTR?= M13M[XNCVkeHUh?=
TC-YIK MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTd6MT6wNUBvVQ>? MXjTRW5ITVJ?
RPMI-8866 M2faVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTnWoo2UUN3ME2xNFA3NjJ6IN88US=> MUnTRW5ITVJ?
KY821 NEHSVVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTFyM{[uNFQh|ryP Mn3rV2FPT0WU
P31-FUJ M4\MNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHyTWM2OD1zMUGyMlc2KM7:TR?= MVLTRW5ITVJ?
COLO-824 NFXMfpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2W2c2lEPTB;MUK2NU44QCEQvF2= NFHxeJlUSU6JRWK=
U-698-M NHPkO5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfRTWM2OD1{Mk[yMlE2KM7:TR?= M2H5cXNCVkeHUh?=
TE-441-T NX72b2RST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmH6TWM2OD1{NUKxMlch|ryP NIfnZXFUSU6JRWK=
IMR-5 MnW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEP5cYJKSzVyPUO0NFkvPjJizszN NV3B[phZW0GQR1XS
NCI-H1838 NXvFUGY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;STWM2OD12MUi2MlMzKM7:TR?= NVjOcodSW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. [2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. [3]

Protocol

Kinase Assay:

[4]

+ Expand

Kinetic Methods:

In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.
Cell Research:

[5]

+ Expand
  • Cell lines: Human multiple myeloma cells line U266
  • Concentrations: ~10 μM
  • Incubation Time: 2 days
  • Method:

    The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: Human plasmacytoma xenografts RPMI 8226
  • Formulation: Saline
  • Dosages: 1 mg/kg
  • Administration: i.v. twice weekly for 4 weeks, then once weekly
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (197.79 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
2% DMSO+30% PEG 300+ddH2O
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 384.24
Formula

C19H25BN4O4

CAS No. 179324-69-7
Storage powder
Synonyms LDP-341, MLM341

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01891968 Completed Leukemia M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. August 7, 2013 Phase 2
NCT01445405 Completed Carcinoma, Squamous|Head and Neck Cancer|Oral Cancer|Laryngeal Cancer|Pharyngeal Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 5, 2008 Phase 1
NCT02211755 Recruiting Neoplasms|Myelodysplastic Syndromes National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 30, 2014 Phase 1
NCT02654990 Recruiting Multiple Myeloma Novartis Pharmaceuticals|Novartis April 27, 2016 Phase 2
NCT00011778 Completed Squamous Cell Carcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 22, 2001 Phase 1
NCT02658396 Withdrawn Multiple Myeloma|Multiple Myeloma in Relapse|Refractory Multiple Myeloma Dana-Farber Cancer Institute|Genus Oncology, LLC|National Institutes of Health (NIH) June 2017 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    On your website, it is mentioned that Bortezomib should be prepared at a concentration of 5 mg/ml in 2% DMSO/30% PEG300/ddH2O for in vivo use. But on the product sheet we received with the compound, it is mentioned: 5mg/ml in 0.5% methylcellulose, 0.2% tween 80. So which is the correct preparation buffer?

  • Answer:

    S1013 Bortezomib in 2% DMSO+30% PEG 300+ddH2O at 5 mg/ml is a clear solution, and it in 0.5% methylcellulose+0.2% Tween 80 is a suspension. Please choose the suitable vehicle according to your administration route. When you prepare the clear solution, please dissolve Bortezomib in DMSO first, make sure it dissolves well, warm it up to 45 degree and/or sonicate if necessary, then add PEG, mix well, and finally add water.

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

Related Proteasome Products

Tags: buy Bortezomib (PS-341) | Bortezomib (PS-341) supplier | purchase Bortezomib (PS-341) | Bortezomib (PS-341) cost | Bortezomib (PS-341) manufacturer | order Bortezomib (PS-341) | Bortezomib (PS-341) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID